Related references
Note: Only part of the references are listed.Engineered Fc based antibody domains and fragments as novel scaffolds
Tianlei Ying et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases
Tianlei Ying et al.
MABS (2014)
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Sung-Youl Ko et al.
NATURE (2014)
Interactions of IgG1 CH2 and CH3 domains with FcRn
Tianlei Ying et al.
FRONTIERS IN IMMUNOLOGY (2014)
Albumin as a versatile platform for drug half-life extension
Darrell Sleep et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Engineered Soluble Monomeric IgG1 CH3 Domain GENERATION, MECHANISMS OF FUNCTION, AND IMPLICATIONS FOR DESIGN OF BIOLOGICAL THERAPEUTICS
Tianlei Ying et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner IMPLICATIONS FOR IN VIVO HALF-LIFE EVALUATION OF ALBUMIN FUSION THERAPEUTICS
Jan Terje Andersen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
The Immunologic Functions of the Neonatal Fc Receptor for IgG
Timo Rath et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery
Eric M. Pridgen et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells
Sandeep Gupta et al.
PLOS PATHOGENS (2013)
Soluble Monomeric IgG1 Fc
Tianlei Ying et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Pharmacokinetics of engineered human monomeric and dimeric CH2 domains
Kurt R. Gehlsen et al.
MABS (2012)
Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
Rui Gong et al.
PLOS ONE (2012)
Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions
Jonathan T. Sockolosky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys
Amita Datta-Mannan et al.
DRUG METABOLISM AND DISPOSITION (2012)
Shortened Engineered Human Antibody CH2 Domains INCREASED STABILITY AND BINDING TO THE HUMAN NEONATAL Fc RECEPTOR
Rui Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Neonatal Fc receptor and IgG-based therapeutics
Timothy T. Kuo et al.
MABS (2011)
Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor
Yang Feng et al.
PROTEIN EXPRESSION AND PURIFICATION (2011)
Neonatal Fc Receptor: From Immunity to Therapeutics
Timothy T. Kuo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky et al.
NATURE BIOTECHNOLOGY (2010)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Development trends for therapeutic antibody fragments
Aaron L. Nelson et al.
NATURE BIOTECHNOLOGY (2009)
Humanized IgG(1) variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates
Amita Datta-Mannan et al.
DRUG METABOLISM AND DISPOSITION (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life
B Gurbaxani et al.
MOLECULAR IMMUNOLOGY (2006)
An engineered human IgG1 antibody with longer serum half-life
PR Hinton et al.
JOURNAL OF IMMUNOLOGY (2006)
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
C Vaccaro et al.
NATURE BIOTECHNOLOGY (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Engineered human IgG antibodies with longer serum half-lives in primates
PR Hinton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex:: Mechanism of pH-dependent binding
WL Martin et al.
MOLECULAR CELL (2001)
Share Paper
